GSK.L - GlaxoSmithKline plc
| Previous close | 1,676.00 |
| Open | 1,692.60 |
| Bid | 1,660.00 x 0 |
| Ask | 1,704.00 x 0 |
| Day's range | 1,687.80 - 1,702.20 |
| 52-week range | 1,408.80 - 1,749.40 |
| Volume | 5,629,496 |
| Avg. volume | 8,543,045 |
| Market cap | 84.364B |
| Beta (3Y monthly) | 0.85 |
| PE ratio (TTM) | 19.05 |
| EPS (TTM) | 88.80 |
| Earnings date | 30 Oct 2019 |
| Forward dividend & yield | 0.76 (4.53%) |
| Ex-dividend date | 2019-08-08 |
| 1y target est | 1,644.50 |
- Simply Wall St.
Do GlaxoSmithKline's (LON:GSK) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Reuters - UK Focus
UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
- Reuters
GSK builds oncology pipeline as drug shown to help myeloma patients
Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion (£4.2 billion) last year and an agreement in February to pay up to 3.7 billion euros (£3.3 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
- Reuters - UK Focus
GSK drug boosts response rates in blood cancer patients -study
- Fool.co.uk
Is the GSK share price worth buying?
GlaxoSmithKline plc (LON: GSK) has posted some good results. But is it worth investing in?
- Reuters
GSK's long acting HIV injection gets boost from study
ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians. It is banking on longer-term studies to yield hard evidence of fewer side effects over time.
- Reuters - UK Focus
MORNING BID EUROPE-To cut or not to cut, that is the question
Target shares surged 20% and Lowe jumped 10%, helping lift Wall Street almost 1% on the day. The Federal Reserve board doesn’t seem to think so -- the July meeting minutes yesterday showed members united in wanting to signal they were not on a pre-set path to more easing. If we get more of that hawkish bent from Fed Chairman Jerome Powell at Jackson Hole tomorrow, it could well dash hopes for a prolonged easing cycle.
- Reuters - UK Focus
UPDATE 2-GSK's long acting HIV injection gets boost from study
GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences. GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit. ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians.
- Reuters - UK Focus
LIVE MARKETS-Heebie-jeebies ahead of PMI data, Brexit, Jackson Hole summit
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Stock futures indicate a weak open in Europe as anxious investors avoid risky bets ahead of UK PM Boris Johnson's meeting with France's Macron today on Brexit, August PMI data from key euro-zone economies and the Jackson Hole summit on Friday. Eurostoxx futures are down 0.2% and the CAC and DAX futures are down 0.3%.
- Business Wire
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen (2DR) of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV. The study was designed to demonstrate the non-inferior antiviral activity and safety of long-acting cabotegravir and rilpivirine administered every eight weeks (two months) compared to every four weeks (monthly) over a 48-week treatment period in adults living with HIV-1 infection whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine.
- Fool.co.uk
Think like Warren Buffett! 2 dividend stocks I’d buy as the FTSE 100 collapses
Don't shrink in the face of diving investor confidence. Grab your debit card and get a slice of these undervalued FTSE 100 (INDEXFTSE: UKX) income heroes, says Royston Wild.
- Motley Fool
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
- Fool.co.uk
Forget 1% from a Cash ISA: I’d pick up 5%+ from these 2 FTSE 100 dividend shares
These two FTSE 100 (INDEXFTSE:UKX) stocks could deliver significantly higher income returns than a Cash ISA in my opinion.
- Reuters - UK Focus
AstraZeneca scores win in race to treat ovarian cancer
AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer. Astra said on Wednesday its Lynparza drug, which blocks a cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body. The patient group that was examined in the so-called Paola-1 trial had been successfully given chemotherapy and Roche's Avastin as initial treatment following a diagnosis of advanced ovarian cancer.
- Reuters - UK Focus
Germany's Stada is "very selective" on acquisitions, CEO says
- Zacks
Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
- Motley Fool
AnaptysBio Prepares for a Potential Gear Shift
During the second quarter, the company upgraded the safety net under its lead candidate.
- Reuters - UK Focus
UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.
- Reuters
GSK ends development of Ebola vaccine, hands work to U.S. institute
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.
- Reuters - UK Focus
GSK hands work on potential Ebola vaccines to U.S. institute
British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo. The vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., GSK said in a statement. The deal will see Sabin continue to develop the candidate vaccines, one of which - a potential Ebola shot known as ChAd3 - has been through mid-stage, Phase II, trials in Africa and could possibly be used to halt or limit future Ebola epidemics.
- Reuters - UK Focus
IBM and other companies launch new blockchain network for supply management
International Business Machines Corp announced on Monday a new blockchain network aimed at improving manual and cumbersome supply chain management. Supply chain management involves overseeing the flow of goods and services, such as tracking the movement and storage of raw materials, inventory, and finished goods. It has been identified as one area that can benefit from blockchain technology, a shared database maintained by a network of computers connected to the internet.
- Simply Wall St.
It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend
GlaxoSmithKline plc (LON:GSK) is about to trade ex-dividend in the next 2 days. You can purchase shares before the 8th...
